Skip to main content
Monday, November 16, 2026Nov 16

With a friend in Trump, the tobacco industry secures a lucrative win

FILE — Dr. Marty Makary, then the Food and Drug Administration commissioner, speaks during an event in the Roosevelt Room of the White House in Washington, Sept. 22, 2025. Makary resigned on Tuesday, May 12, telling associates he could not remain the head of an agency that backed the Trump administration’s new vape policy. (Tierney L. Cross/The New York Times)
FILE — Dr. Marty Makary, then the Food and Drug Administration commissioner, speaks during an event in the Roosevelt Room of the White House in Washington, Sept. 22, 2025. Makary resigned on Tuesday, May 12, telling associates he could not remain the head of an agency that backed the Trump administration’s new vape policy. (Tierney L. Cross/The New York Times)

WASHINGTON — Over lunch at his golf club in Jupiter, Florida, on the first Saturday of May, President Donald Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.

Eventually Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the FDA commissioner.

No answer.

Furious, the president then dialed Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the FDA’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.

The message was received. Less than one week later, the executives got what they wanted.